Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent
Sponsors
Centre hospitalier universitaire de Liege, Gentofte Hospital, Pfizer Inc., Region Skane, Centre Hospitalier Annecy Genevois, Fondazione Penta Ets
Conditions
BronchiolitisInflammatory rheumatic diseaseRSV-infectionRespiratory Syncytial Virus (RSV)Respiratory syncytial virus infectionRespiratory tract infectionallogeneic - Hematopoietic Stem Cell Transplantation
Phase 2
Phase 3
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
Not yet recruitingCTIS2025-521755-23-00
Target: 2000Updated: 2025-10-21
Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial
Not yet recruitingCTIS2025-522194-11-00
Target: 400Updated: 2025-11-04
Phase 4
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above (DAN-RSV)
RecruitingCTIS2024-516600-42-00
Start: 2024-11-18Target: 890000Updated: 2025-11-03
Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.
Not yet recruitingCTIS2024-518191-31-00
Target: 180Updated: 2025-07-09